Shots:
- Meiji and Dong-A ST to receive an upfront & will be eligible to receive development & sales milestones along with profit share. The companies collaborated to commercialize DMB-3115 proposed biosimilar to ustekinumab for the treatment of inflammatory diseases such as PsO, CD & UC
- Intas to get exclusive license rights to commercialize DMB-3115 globally, Ex-Japan, Korea & Asia. Meiji and Dong-A ST will develop and manufacture DMB-3115 and supply the product to Intas and its WW affiliates
- DMB-3115 is being evaluated in a P-III multi-regional clinical trial to treat patients with PsO in the EU & US
Click here to read full press release/ article | Ref: Meiji | Image: Meiji
The post Meiji and Dong-A ST Sign an Exclusive License Agreement with Intas to Commercialize DMB-3115, Proposed Biosimilar to Ustekinumab first appeared on PharmaShots.
